The British Journal of Rheumatology, Vol 36, 643-650, Copyright © 1997 by British Society for Rheumatology
FM Brennan, KA Browne, PA Green, JM Jaspar, RN Maini and M Feldmann
Matrix metalloproteinase (MMP)-1 and MMP-3 levels were measured in serum
samples from rheumatoid arthritis (RA) patients undergoing a double-blinded
placebo-controlled trial with the chimaeric anti-tumour necrosis factor
(TNF)-alpha antibody cA2. Both MMP-1 (P < 0.015), but to a larger extent
MMP-3 (P < 0.001) levels were elevated in all RA patients prior to the
commencement of the trial compared with normal control sera. Following cA2
therapy, MMP-1 and MMP-3 levels were assessed in the placebo, and 1 and 10
mg/kg cA2-treated groups at 7, 14, 21 and 28 days. In both the 1 and the 10
mg/kg cA2-treated groups, a significant decrease in serum MMP-3 levels at
all time points was observed, reducing maximally to 41% of pre-infusion
values at day 7. MMP-1 levels were also reduced, but less dramatically than
MMP-3, to 85% of pre-infusion values after 14 days in the 10 mg/kg cA2
treated group. In a separate non-placebo-controlled study, we also
evaluated the tissue inhibitor of metalloproteinase (TIMP)-1 levels in
plasma following cA2 infusion. Pre-infusion TIMP-1 levels were above the
normal control range, but were significantly reduced (P < 0.035) 14 days
after infusion to 72% of pre-infusion values. This study confirms previous
reports that MMP-3 levels are elevated and correlate with measures of
inflammation in RA, and furthermore demonstrate that serum MMP-3 and MMP-1
levels are downmodulated following anti-TNF-alpha antibody therapy. Whilst
serum MMP-3 levels correlated with C-reactive protein (CRP) both prior to
and following anti-TNF-alpha antibody therapy, it remains to be
demonstrated that serum MMP-3 and/or MMP-1 levels reflect the cartilage and
bone resorptive processes which are evident in this disease.
ORIGINAL PAPERS
Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti- tumour necrosis factor-alpha (cA2) therapy
Kennedy Institute of Rheumatology, Hammersmith, London.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Iikuni, E. Inoue, E. Tanaka, M. Hara, T. Tomatsu, N. Kamatani, and H. Yamanaka Low disease activity state with corticosteroid may not represent 'true' low disease activity state in patients with rheumatoid arthritis Rheumatology, April 1, 2008; 47(4): 519 - 521. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Chopin, P Garnero, A le Henanff, F Debiais, A Daragon, C Roux, J Sany, D Wendling, C Zarnitsky, P Ravaud, et al. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis Ann Rheum Dis, March 1, 2008; 67(3): 353 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E Furst, N. Gaylis, V. Bray, E. Olech, D. Yocum, J. Ritter, M. Weisman, D. J Wallace, J. Crues, D. Khanna, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study Ann Rheum Dis, July 1, 2007; 66(7): 893 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kamata, S. Kamijo, A. Nakajima, A. Koyanagi, H. Kurosawa, H. Yagita, and K. Okumura Involvement of TNF-Like Weak Inducer of Apoptosis in the Pathogenesis of Collagen-Induced Arthritis J. Immunol., November 1, 2006; 177(9): 6433 - 6439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ehling, A. Schaffler, H. Herfarth, I. H. Tarner, S. Anders, O. Distler, G. Paul, J. Distler, S. Gay, J. Scholmerich, et al. The Potential of Adiponectin in Driving Arthritis J. Immunol., April 1, 2006; 176(7): 4468 - 4478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W Hui, H E Barksby, D A Young, T E Cawston, N McKie, and A D Rowan Oncostatin M in combination with tumour necrosis factor {alpha} induces a chondrocyte membrane associated aggrecanase that is distinct from ADAMTS aggrecanase-1 or -2 Ann Rheum Dis, November 1, 2005; 64(11): 1624 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Gottlieb, F. Chamian, S. Masud, I. Cardinale, M. V. Abello, M. A. Lowes, F. Chen, M. Magliocco, and J. G. Krueger TNF Inhibition Rapidly Down-Regulates Multiple Proinflammatory Pathways in Psoriasis Plaques J. Immunol., August 15, 2005; 175(4): 2721 - 2729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P Durez, A Nzeusseu Toukap, B R Lauwerys, D H Manicourt, P Verschueren, R Westhovens, J-P Devogelaer, and F A Houssiau A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment Ann Rheum Dis, September 1, 2004; 63(9): 1069 - 1074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Aggarwal, S Panda, and R Misra Effect of etanercept on matrix metalloproteinases and angiogenic vascular endothelial growth factor: a time kinetic study Ann Rheum Dis, July 1, 2004; 63(7): 891 - 892. [Full Text]
|
|
|
|
|
|
A. Myers, R. Lakey, T. E. Cawston, L. J. Kay, and D. J. Walker Serum MMP-1 and TIMP-1 levels are increased in patients with psoriatic arthritis and their siblings Rheumatology, March 1, 2004; 43(3): 272 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Rowan, W. Hui, T. E. Cawston, and C. D. Richards Adenoviral Gene Transfer of Interleukin-1 in Combination with Oncostatin M Induces Significant Joint Damage in a Murine Model Am. J. Pathol., June 1, 2003; 162(6): 1975 - 1984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. I. Catrina, J. Lampa, S. Ernestam, E. af Klint, J. Bratt, L. Klareskog, and A.-K. Ulfgren Anti-tumour necrosis factor (TNF)-{alpha} therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis Rheumatology, May 1, 2002; 41(5): 484 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A A den Broeder, L A B Joosten, T Saxne, D Heinegard, H Fenner, A M M Miltenburg, W L H Frasa, L J van Tits, W A Buurman, P L C M van Riel, et al. Long term anti-tumour necrosis factor {alpha} monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation Ann Rheum Dis, April 1, 2002; 61(4): 311 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Drynda, C Kuhne, and J Kekow Soluble tumour necrosis factor receptor treatment does not affect raised transforming growth factor {beta} levels in rheumatoid arthritis Ann Rheum Dis, March 1, 2002; 61(3): 254 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Ribbens, M Martin y Porras, N Franchimont, M-J Kaiser, J-M Jaspar, P Damas, F A Houssiau, and M G Malaise Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment Ann Rheum Dis, February 1, 2002; 61(2): 161 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. B. McInnes, G. G. Illei, C. L. Danning, C. H. Yarboro, M. Crane, T. Kuroiwa, R. Schlimgen, E. Lee, B. Foster, D. Flemming, et al. IL-10 Improves Skin Disease and Modulates Endothelial Activation and Leukocyte Effector Function in Patients with Psoriatic Arthritis J. Immunol., October 1, 2001; 167(7): 4075 - 4082. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Roux-Lombard, K. Eberhardt, T. Saxne, J.-M. Dayer, and F. A. Wollheim Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study Rheumatology, May 1, 2001; 40(5): 544 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ribbens, B. Andre, O. Kaye, M.-J. Kaiser, V. Bonnet, J.-M. Jaspar, D. de Groote, N. Franchimont, and M. G. Malaise Synovial fluid matrix metalloproteinase-3 levels are increased in inflammatory arthritides whether erosive or not Rheumatology, December 1, 2000; 39(12): 1357 - 1365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Stallmach, C C Chan, K-W Ecker, G Feifel, H Herbst, D Schuppan, and M Zeitz Comparable expression of matrix metalloproteinases 1 and 2 in pouchitis and ulcerative colitis Gut, September 1, 2000; 47(3): 415 - 422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R B Heuschkel, T T MacDonald, G Monteleone, M Bajaj-Elliott, J A W. Smith, and S L F Pender Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease Gut, July 1, 2000; 47(1): 57 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Posthumus, P. C. Limburg, J. Westra, H. A. Cats, R. E. Stewart, M. A. van Leeuwen, and M. H. van Rijswijk Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis Rheumatology, November 1, 1999; 38(11): 1081 - 1087. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Bondeson, B. Foxwell, F. Brennan, and M. Feldmann Defining therapeutic targets by using adenovirus: Blocking NF-kappa B inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators PNAS, May 11, 1999; 96(10): 5668 - 5673. [Abstract] [Full Text] [PDF]
|
|